financetom
Business
financetom
/
Business
/
Chili's owner Brinker posts higher Q4 revenue 
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Chili's owner Brinker posts higher Q4 revenue 
Aug 13, 2025 4:12 AM

Overview

* Brinker ( EAT ) Q4 fiscal 2025 revenue rises 21%, beating analyst expectations, per LSEG data

* Adjusted EPS for Q4 fiscal 2025 beats consensus, reflecting operational efficiencies, per LSEG data

* Co authorizes additional $400 mln for share repurchase program, indicating financial confidence

Outlook

* Brinker ( EAT ) expects fiscal 2026 revenue between $5.60 bln and $5.70 bln

* Company forecasts fiscal 2026 EPS excluding special items at $9.90-$10.50

* Brinker ( EAT ) anticipates fiscal 2026 capital expenditures of $270 mln-$290 mln

* Company sees fiscal 2026 weighted average shares at 45 mln-46 mln

Result Drivers

* CHILIS SALES GROWTH - Driven by increased traffic, menu innovation, and advertising, per CEO Kevin Hochman

* OPERATIONAL IMPROVEMENTS - Contributed to traffic gains and repeat guest visits

* MAGGIANOS SALES DECLINE - Due to lower traffic, partially offset by menu pricing

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q4 Beat $1.46 $1.44

Revenue bln bln (15

Analysts

)

Q4 Beat $2.49 $2.45

Adjusted (18

EPS Analysts

)

Q4 EPS $2.3

Q4 21.3%

Like-For

-Like

Growth

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 5 "strong buy" or "buy", 15 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the restaurants & bars peer group is "buy."

* Wall Street's median 12-month price target for Brinker International Inc ( EAT ) is $167.00, about 7.3% above its August 12 closing price of $154.88

* The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 14 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
--Street Color: Exxon Mobil Investing $100 Million to Upgrade Louisiana Chemical Plant for Alcohol Production, Reuters Says
--Street Color: Exxon Mobil Investing $100 Million to Upgrade Louisiana Chemical Plant for Alcohol Production, Reuters Says
Mar 26, 2025
10:29 AM EDT, 03/26/2025 (MT Newswires) -- Price: 118.83, Change: +2.24, Percent Change: +1.92 ...
Avalo Therapeutics Names Michael Heffernan as Board Chairman
Avalo Therapeutics Names Michael Heffernan as Board Chairman
Mar 26, 2025
10:18 AM EDT, 03/26/2025 (MT Newswires) -- Avalo Therapeutics ( AVTX ) said Wednesday that Michael Heffernan has been named board chairman, succeeding Garry Neil. Neil will continue as chief executive officer and board member, the company said. Heffernan is the founder and chairman of Collegium Pharmaceutical (COLL), where he also previously served as president and CEO, Avalo said. Avalo...
Jinxin Technology Issues 2025 Outlook; Shares Rise
Jinxin Technology Issues 2025 Outlook; Shares Rise
Mar 26, 2025
10:27 AM EDT, 03/26/2025 (MT Newswires) -- Jinxin Technology ( NAMI ) said Wednesday it expects fiscal 2025 revenue of $70 million, supported by growth across its AI-powered product portfolio and strategic partnerships. The company expects its collaboration with China Mobile under the 5G New Call project to generate over 100 million yuan ($13.8 million) in revenue and attract more...
Rafael Closes Merger With Cyclo Therapeutics
Rafael Closes Merger With Cyclo Therapeutics
Mar 26, 2025
10:22 AM EDT, 03/26/2025 (MT Newswires) -- Rafael Holdings ( RFL ) and Cyclo Therapeutics ( CYTH ) said Wednesday they have completed their merger following shareholders' approval from both companies. Rafael ( RFL ) issued Class B shares, representing 22% of the combined business, to the shareholders of Cyclo Therapeutics ( CYTH ), based on the exchange ratio determined...
Copyright 2023-2026 - www.financetom.com All Rights Reserved